A 35-year-old man with a history of seasonal allergic rhinitis presents with acute onset of severe dyspnea, wheezing, and chest tightness 20 minutes after inhaling dust from stored grain in his warehouse. He is alert, SpO₂ 88% on room air, and peak expiratory flow is 40% of predicted. He has no prior anaphylaxis. What is the most appropriate immediate next step in management?

Explanation

## Clinical Presentation & Diagnosis This is a **Type I hypersensitivity reaction presenting as acute asthma exacerbation** (not anaphylaxis). The distinguishing features are: - **Respiratory symptoms only** (dyspnea, wheezing, chest tightness) - **No systemic signs:** no angioedema, no urticaria, no hypotension, alert and oriented - **Hypoxemia** (SpO₂ 88%) with reduced peak flow (40% of predicted) - **Trigger:** inhaled allergen (grain dust) - **Atopic history:** seasonal allergic rhinitis **Key Point:** This is **acute asthma exacerbation, not anaphylaxis.** Anaphylaxis requires systemic manifestations (skin, GI, cardiovascular, or airway edema). Isolated bronchospasm is managed with **rapid-acting bronchodilators**, not epinephrine. ## Why Inhaled Albuterol Is First-Line **High-Yield:** In acute asthma exacerbation (even severe), the first-line agent is a **rapid-acting β₂-agonist** (albuterol/salbutamol): - **Mechanism:** β₂-adrenergic stimulation → smooth muscle relaxation → rapid bronchodilation - **Onset:** 5–15 minutes via nebulizer - **Efficacy:** reverses bronchospasm in 80–90% of cases - **Safety:** no systemic side effects at therapeutic doses **Clinical Pearl:** Epinephrine is **not indicated** for isolated bronchospasm because: - The non-selective α-adrenergic effects cause vasoconstriction, which can worsen hypoxemia in some patients - β₂-agonists are more selective and effective for airway smooth muscle - Epinephrine is reserved for **anaphylaxis with systemic signs** (angioedema, hypotension, urticaria) ## Management Algorithm for Acute Asthma Exacerbation ```mermaid flowchart TD A[Acute asthma exacerbation: dyspnea + wheezing + hypoxemia]:::outcome --> B[Assess severity]:::decision B --> C[Mild-moderate: PEF > 50%]:::outcome B --> D[Severe: PEF 25-50%]:::outcome B --> E[Life-threatening: PEF < 25%, silent chest, confusion]:::urgent C --> F[Inhaled albuterol via nebulizer]:::action D --> G[Inhaled albuterol + systemic corticosteroids]:::action E --> H[High-flow O₂ + albuterol + IV corticosteroids + consider IV magnesium]:::urgent F --> I{Response in 1-2 hours?}:::decision G --> I I -->|Good| J[Discharge with oral corticosteroids + inhaler]:::action I -->|Poor| K[Admit for observation ± ICU]:::action E --> L{Intubation needed?}:::decision L -->|Yes| M[Emergency intubation]:::urgent L -->|No| K ``` **Key Point:** Intubation is a **rescue measure** for life-threatening asthma (altered mental status, silent chest, PEF < 25%, inability to speak). This patient is alert with SpO₂ 88% — he is **severe but not yet life-threatening** and should respond to bronchodilators. ## Comparison: Asthma vs. Anaphylaxis | Feature | Acute Asthma | Anaphylaxis | | --- | --- | --- | | **Onset** | Minutes to hours | Seconds to minutes | | **Respiratory** | Bronchospasm (wheezing) | Angioedema ± bronchospasm | | **Skin** | Absent | Urticaria, flushing | | **Cardiovascular** | Normal BP initially | Hypotension, shock | | **GI** | Absent | Nausea, vomiting, diarrhea | | **First-line drug** | Albuterol | Epinephrine IM | **Warning:** Do not confuse **anaphylaxis with asthma.** Epinephrine is not first-line for isolated bronchospasm. [cite:Harrison 21e Ch 334; Robbins 10e Ch 6]